[GetPortalCommentsPageByObjectIdResponse(id=509070, encodeId=95d45090e0b0, content=一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=383, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723f1608660, createdName=fengjie741, createdTime=Sat Jan 10 11:45:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502951, encodeId=5a94502951ef, content=经典期刊~等待雄起啊~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri May 16 16:00:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502162, encodeId=5a5650216217, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：2010年11月底抱着试试看的心情，刚写完的manuscript第一次就投给了BLOOD，没想到格外幸运，两个审稿人一审就给出了 minor revision 的意见（2011年1月，审稿用时8周），比较少见，大体上非常supportive，于是花了两个月补充了两三个小实验，修改了一些文章细节，追加了一些讨论分析；2011年4月投回去，然后过了一周就接收了。后来这几年里自己的其他文章又陆续投过比BLOOD低分的杂志，都没再有如此顺利的呵呵，都是先major revision再minor revision的折腾，相信同行们都理解这些历程的~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=路人熊医师, createdTime=Fri Apr 04 08:52:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490209, encodeId=81654902094b, content=审稿速度:2.0<br>经验分享：今年文章 第一次投BLOOD， 只是试一试而已， 侥幸通过。 两位评审还比较NICE， 没有提出多少补充实验。。。文章要求数据很牢靠， 总结了前十几年在自己研究领域课题的争议， 提出自己的观点给予验证，实验结果不仅需要现象， 还要机制说明。 给大家参考一下自己投稿的时间！ <br> <br> Submission date: 22 Mar 2012 <br> Major Revision: 7 May 2012 <br> Revision received: 12 Jul 2012 <br> Minor Revision: 14 Aug 2012 <br> Revision received: 20 Aug 2012 <br> Accepted: 24 Aug 2012 <br> <br> 谢谢对大家的支持和努力！再接再厉做好科研！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea66634, createdName=alansb, createdTime=Sun Aug 26 08:00:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=475571, encodeId=04ea4e557167, content=出版周期：Semimonthly <br> 出版ISSN：0006-4971 <br> Blood是隶属于美国血液学会ASH的周刊，是血液领域的顶级杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e7c34764, createdName=marshlin, createdTime=Wed Jun 29 12:10:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=470004, encodeId=d4744e00041e, content=杂志名称： BLOOD <br> 专业领域： 血液，移植，免疫，干细胞，肿瘤 <br> 杂志国家： 美国 <br> 投稿日期：16 Jul 2009 <br> 投稿方式（投稿系统或者邮寄，如果有投稿系统请附上投稿链接）： <br> 在线投稿 http://submit.bloodjournal.org/ <br> 修回日期： 无 <br> 修改方式（大修，小修，拒稿）：拒稿 <br> 接受日期： 无 <br> 是否收版面费： 还不知道呢，呵呵。 <br> 分享的经验或教训：感觉对我们搞基础研究的，BLOOD这种杂志越来越难投了，杂志上很多文章都是很偏临床的，基础的很少。该杂志效率还是很高的，如果送外审的话，也是一个月给决定。我们这次因为两个reviewer意见不太一致，所以又找了第三个reviewer，（所以花了5个星期做决定）结果后者给了大修的建议，综合起来意见比较负面，编辑决定拒稿。 <br> <br> 附上decison letter <br> Dear Dr. XXX: <br> <br> Expert reviewers in the field have evaluated your manuscript, referenced above. Unfortunately, our final decision is that your paper is not acceptable for publication in Blood. You can log into Blood Bench>Press at http://submit.bloodjournal.org and go to the queue "Manuscripts with Decisions" to <br> find this submission and access any reviewer comments. <br> <br> Concerns were raised about the reliance on a small number of cell lines and the reasons for selecting XXXX over numerous other possible candidates. <br> <br> You will appreciate that the number of manuscripts submitted to Blood for publication consideration is very high and that we are currently able to accept no more than 20% of submitted manuscripts. <br> <br> Consequently, the journal can only accept papers that receive a high priority rating based on the definitive and novel nature of the findings reported. <br> <br> I regret the negative decision on this manuscript, but thank you for sending it to Blood for consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=river33617, createdTime=Fri Jan 01 17:20:00 CST 2010, time=2010-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469745, encodeId=41a2469e459c, content=我们实验室几乎每年都有，虽然说是血液病中顶级杂志，但在国内，仍然与CNS级差得远。一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=496, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CAS, createdTime=Tue Dec 15 14:22:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469450, encodeId=0cac469450b7, content=一审周期在1个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ZHAO, createdTime=Fri Nov 20 15:56:00 CST 2009, time=2009-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469363, encodeId=3dce46936369, content=血液领域的最权威杂志了，国内有几个投稿大户，如陈国强，陈竺那里，发表起来不太难。但是要求实验非常完善，技术方法都要求新，而且有原创的发现。 <br> 当然，如果这个发不了，可以考虑低一层次的《白血病》，也不错。另外，现在不少牛人，好文章也逐步离开blood，跑其它的地方去了哦，如nature medicine等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=394, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=血液科医生, createdTime=Mon Oct 05 16:00:00 CST 2009, time=2009-10-05, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=509070, encodeId=95d45090e0b0, content=一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=383, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723f1608660, createdName=fengjie741, createdTime=Sat Jan 10 11:45:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502951, encodeId=5a94502951ef, content=经典期刊~等待雄起啊~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri May 16 16:00:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502162, encodeId=5a5650216217, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：2010年11月底抱着试试看的心情，刚写完的manuscript第一次就投给了BLOOD，没想到格外幸运，两个审稿人一审就给出了 minor revision 的意见（2011年1月，审稿用时8周），比较少见，大体上非常supportive，于是花了两个月补充了两三个小实验，修改了一些文章细节，追加了一些讨论分析；2011年4月投回去，然后过了一周就接收了。后来这几年里自己的其他文章又陆续投过比BLOOD低分的杂志，都没再有如此顺利的呵呵，都是先major revision再minor revision的折腾，相信同行们都理解这些历程的~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=路人熊医师, createdTime=Fri Apr 04 08:52:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490209, encodeId=81654902094b, content=审稿速度:2.0<br>经验分享：今年文章 第一次投BLOOD， 只是试一试而已， 侥幸通过。 两位评审还比较NICE， 没有提出多少补充实验。。。文章要求数据很牢靠， 总结了前十几年在自己研究领域课题的争议， 提出自己的观点给予验证，实验结果不仅需要现象， 还要机制说明。 给大家参考一下自己投稿的时间！ <br> <br> Submission date: 22 Mar 2012 <br> Major Revision: 7 May 2012 <br> Revision received: 12 Jul 2012 <br> Minor Revision: 14 Aug 2012 <br> Revision received: 20 Aug 2012 <br> Accepted: 24 Aug 2012 <br> <br> 谢谢对大家的支持和努力！再接再厉做好科研！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea66634, createdName=alansb, createdTime=Sun Aug 26 08:00:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=475571, encodeId=04ea4e557167, content=出版周期：Semimonthly <br> 出版ISSN：0006-4971 <br> Blood是隶属于美国血液学会ASH的周刊，是血液领域的顶级杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e7c34764, createdName=marshlin, createdTime=Wed Jun 29 12:10:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=470004, encodeId=d4744e00041e, content=杂志名称： BLOOD <br> 专业领域： 血液，移植，免疫，干细胞，肿瘤 <br> 杂志国家： 美国 <br> 投稿日期：16 Jul 2009 <br> 投稿方式（投稿系统或者邮寄，如果有投稿系统请附上投稿链接）： <br> 在线投稿 http://submit.bloodjournal.org/ <br> 修回日期： 无 <br> 修改方式（大修，小修，拒稿）：拒稿 <br> 接受日期： 无 <br> 是否收版面费： 还不知道呢，呵呵。 <br> 分享的经验或教训：感觉对我们搞基础研究的，BLOOD这种杂志越来越难投了，杂志上很多文章都是很偏临床的，基础的很少。该杂志效率还是很高的，如果送外审的话，也是一个月给决定。我们这次因为两个reviewer意见不太一致，所以又找了第三个reviewer，（所以花了5个星期做决定）结果后者给了大修的建议，综合起来意见比较负面，编辑决定拒稿。 <br> <br> 附上decison letter <br> Dear Dr. XXX: <br> <br> Expert reviewers in the field have evaluated your manuscript, referenced above. Unfortunately, our final decision is that your paper is not acceptable for publication in Blood. You can log into Blood Bench>Press at http://submit.bloodjournal.org and go to the queue "Manuscripts with Decisions" to <br> find this submission and access any reviewer comments. <br> <br> Concerns were raised about the reliance on a small number of cell lines and the reasons for selecting XXXX over numerous other possible candidates. <br> <br> You will appreciate that the number of manuscripts submitted to Blood for publication consideration is very high and that we are currently able to accept no more than 20% of submitted manuscripts. <br> <br> Consequently, the journal can only accept papers that receive a high priority rating based on the definitive and novel nature of the findings reported. <br> <br> I regret the negative decision on this manuscript, but thank you for sending it to Blood for consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=river33617, createdTime=Fri Jan 01 17:20:00 CST 2010, time=2010-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469745, encodeId=41a2469e459c, content=我们实验室几乎每年都有，虽然说是血液病中顶级杂志，但在国内，仍然与CNS级差得远。一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=496, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CAS, createdTime=Tue Dec 15 14:22:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469450, encodeId=0cac469450b7, content=一审周期在1个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ZHAO, createdTime=Fri Nov 20 15:56:00 CST 2009, time=2009-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469363, encodeId=3dce46936369, content=血液领域的最权威杂志了，国内有几个投稿大户，如陈国强，陈竺那里，发表起来不太难。但是要求实验非常完善，技术方法都要求新，而且有原创的发现。 <br> 当然，如果这个发不了，可以考虑低一层次的《白血病》，也不错。另外，现在不少牛人，好文章也逐步离开blood，跑其它的地方去了哦，如nature medicine等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=394, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=血液科医生, createdTime=Mon Oct 05 16:00:00 CST 2009, time=2009-10-05, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=509070, encodeId=95d45090e0b0, content=一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=383, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723f1608660, createdName=fengjie741, createdTime=Sat Jan 10 11:45:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502951, encodeId=5a94502951ef, content=经典期刊~等待雄起啊~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri May 16 16:00:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502162, encodeId=5a5650216217, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：2010年11月底抱着试试看的心情，刚写完的manuscript第一次就投给了BLOOD，没想到格外幸运，两个审稿人一审就给出了 minor revision 的意见（2011年1月，审稿用时8周），比较少见，大体上非常supportive，于是花了两个月补充了两三个小实验，修改了一些文章细节，追加了一些讨论分析；2011年4月投回去，然后过了一周就接收了。后来这几年里自己的其他文章又陆续投过比BLOOD低分的杂志，都没再有如此顺利的呵呵，都是先major revision再minor revision的折腾，相信同行们都理解这些历程的~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=路人熊医师, createdTime=Fri Apr 04 08:52:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490209, encodeId=81654902094b, content=审稿速度:2.0<br>经验分享：今年文章 第一次投BLOOD， 只是试一试而已， 侥幸通过。 两位评审还比较NICE， 没有提出多少补充实验。。。文章要求数据很牢靠， 总结了前十几年在自己研究领域课题的争议， 提出自己的观点给予验证，实验结果不仅需要现象， 还要机制说明。 给大家参考一下自己投稿的时间！ <br> <br> Submission date: 22 Mar 2012 <br> Major Revision: 7 May 2012 <br> Revision received: 12 Jul 2012 <br> Minor Revision: 14 Aug 2012 <br> Revision received: 20 Aug 2012 <br> Accepted: 24 Aug 2012 <br> <br> 谢谢对大家的支持和努力！再接再厉做好科研！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea66634, createdName=alansb, createdTime=Sun Aug 26 08:00:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=475571, encodeId=04ea4e557167, content=出版周期：Semimonthly <br> 出版ISSN：0006-4971 <br> Blood是隶属于美国血液学会ASH的周刊，是血液领域的顶级杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e7c34764, createdName=marshlin, createdTime=Wed Jun 29 12:10:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=470004, encodeId=d4744e00041e, content=杂志名称： BLOOD <br> 专业领域： 血液，移植，免疫，干细胞，肿瘤 <br> 杂志国家： 美国 <br> 投稿日期：16 Jul 2009 <br> 投稿方式（投稿系统或者邮寄，如果有投稿系统请附上投稿链接）： <br> 在线投稿 http://submit.bloodjournal.org/ <br> 修回日期： 无 <br> 修改方式（大修，小修，拒稿）：拒稿 <br> 接受日期： 无 <br> 是否收版面费： 还不知道呢，呵呵。 <br> 分享的经验或教训：感觉对我们搞基础研究的，BLOOD这种杂志越来越难投了，杂志上很多文章都是很偏临床的，基础的很少。该杂志效率还是很高的，如果送外审的话，也是一个月给决定。我们这次因为两个reviewer意见不太一致，所以又找了第三个reviewer，（所以花了5个星期做决定）结果后者给了大修的建议，综合起来意见比较负面，编辑决定拒稿。 <br> <br> 附上decison letter <br> Dear Dr. XXX: <br> <br> Expert reviewers in the field have evaluated your manuscript, referenced above. Unfortunately, our final decision is that your paper is not acceptable for publication in Blood. You can log into Blood Bench>Press at http://submit.bloodjournal.org and go to the queue "Manuscripts with Decisions" to <br> find this submission and access any reviewer comments. <br> <br> Concerns were raised about the reliance on a small number of cell lines and the reasons for selecting XXXX over numerous other possible candidates. <br> <br> You will appreciate that the number of manuscripts submitted to Blood for publication consideration is very high and that we are currently able to accept no more than 20% of submitted manuscripts. <br> <br> Consequently, the journal can only accept papers that receive a high priority rating based on the definitive and novel nature of the findings reported. <br> <br> I regret the negative decision on this manuscript, but thank you for sending it to Blood for consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=river33617, createdTime=Fri Jan 01 17:20:00 CST 2010, time=2010-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469745, encodeId=41a2469e459c, content=我们实验室几乎每年都有，虽然说是血液病中顶级杂志，但在国内，仍然与CNS级差得远。一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=496, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CAS, createdTime=Tue Dec 15 14:22:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469450, encodeId=0cac469450b7, content=一审周期在1个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ZHAO, createdTime=Fri Nov 20 15:56:00 CST 2009, time=2009-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469363, encodeId=3dce46936369, content=血液领域的最权威杂志了，国内有几个投稿大户，如陈国强，陈竺那里，发表起来不太难。但是要求实验非常完善，技术方法都要求新，而且有原创的发现。 <br> 当然，如果这个发不了，可以考虑低一层次的《白血病》，也不错。另外，现在不少牛人，好文章也逐步离开blood，跑其它的地方去了哦，如nature medicine等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=394, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=血液科医生, createdTime=Mon Oct 05 16:00:00 CST 2009, time=2009-10-05, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=509070, encodeId=95d45090e0b0, content=一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=383, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723f1608660, createdName=fengjie741, createdTime=Sat Jan 10 11:45:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502951, encodeId=5a94502951ef, content=经典期刊~等待雄起啊~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri May 16 16:00:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502162, encodeId=5a5650216217, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：2010年11月底抱着试试看的心情，刚写完的manuscript第一次就投给了BLOOD，没想到格外幸运，两个审稿人一审就给出了 minor revision 的意见（2011年1月，审稿用时8周），比较少见，大体上非常supportive，于是花了两个月补充了两三个小实验，修改了一些文章细节，追加了一些讨论分析；2011年4月投回去，然后过了一周就接收了。后来这几年里自己的其他文章又陆续投过比BLOOD低分的杂志，都没再有如此顺利的呵呵，都是先major revision再minor revision的折腾，相信同行们都理解这些历程的~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=路人熊医师, createdTime=Fri Apr 04 08:52:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490209, encodeId=81654902094b, content=审稿速度:2.0<br>经验分享：今年文章 第一次投BLOOD， 只是试一试而已， 侥幸通过。 两位评审还比较NICE， 没有提出多少补充实验。。。文章要求数据很牢靠， 总结了前十几年在自己研究领域课题的争议， 提出自己的观点给予验证，实验结果不仅需要现象， 还要机制说明。 给大家参考一下自己投稿的时间！ <br> <br> Submission date: 22 Mar 2012 <br> Major Revision: 7 May 2012 <br> Revision received: 12 Jul 2012 <br> Minor Revision: 14 Aug 2012 <br> Revision received: 20 Aug 2012 <br> Accepted: 24 Aug 2012 <br> <br> 谢谢对大家的支持和努力！再接再厉做好科研！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea66634, createdName=alansb, createdTime=Sun Aug 26 08:00:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=475571, encodeId=04ea4e557167, content=出版周期：Semimonthly <br> 出版ISSN：0006-4971 <br> Blood是隶属于美国血液学会ASH的周刊，是血液领域的顶级杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e7c34764, createdName=marshlin, createdTime=Wed Jun 29 12:10:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=470004, encodeId=d4744e00041e, content=杂志名称： BLOOD <br> 专业领域： 血液，移植，免疫，干细胞，肿瘤 <br> 杂志国家： 美国 <br> 投稿日期：16 Jul 2009 <br> 投稿方式（投稿系统或者邮寄，如果有投稿系统请附上投稿链接）： <br> 在线投稿 http://submit.bloodjournal.org/ <br> 修回日期： 无 <br> 修改方式（大修，小修，拒稿）：拒稿 <br> 接受日期： 无 <br> 是否收版面费： 还不知道呢，呵呵。 <br> 分享的经验或教训：感觉对我们搞基础研究的，BLOOD这种杂志越来越难投了，杂志上很多文章都是很偏临床的，基础的很少。该杂志效率还是很高的，如果送外审的话，也是一个月给决定。我们这次因为两个reviewer意见不太一致，所以又找了第三个reviewer，（所以花了5个星期做决定）结果后者给了大修的建议，综合起来意见比较负面，编辑决定拒稿。 <br> <br> 附上decison letter <br> Dear Dr. XXX: <br> <br> Expert reviewers in the field have evaluated your manuscript, referenced above. Unfortunately, our final decision is that your paper is not acceptable for publication in Blood. You can log into Blood Bench>Press at http://submit.bloodjournal.org and go to the queue "Manuscripts with Decisions" to <br> find this submission and access any reviewer comments. <br> <br> Concerns were raised about the reliance on a small number of cell lines and the reasons for selecting XXXX over numerous other possible candidates. <br> <br> You will appreciate that the number of manuscripts submitted to Blood for publication consideration is very high and that we are currently able to accept no more than 20% of submitted manuscripts. <br> <br> Consequently, the journal can only accept papers that receive a high priority rating based on the definitive and novel nature of the findings reported. <br> <br> I regret the negative decision on this manuscript, but thank you for sending it to Blood for consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=river33617, createdTime=Fri Jan 01 17:20:00 CST 2010, time=2010-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469745, encodeId=41a2469e459c, content=我们实验室几乎每年都有，虽然说是血液病中顶级杂志，但在国内，仍然与CNS级差得远。一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=496, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CAS, createdTime=Tue Dec 15 14:22:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469450, encodeId=0cac469450b7, content=一审周期在1个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ZHAO, createdTime=Fri Nov 20 15:56:00 CST 2009, time=2009-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469363, encodeId=3dce46936369, content=血液领域的最权威杂志了，国内有几个投稿大户，如陈国强，陈竺那里，发表起来不太难。但是要求实验非常完善，技术方法都要求新，而且有原创的发现。 <br> 当然，如果这个发不了，可以考虑低一层次的《白血病》，也不错。另外，现在不少牛人，好文章也逐步离开blood，跑其它的地方去了哦，如nature medicine等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=394, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=血液科医生, createdTime=Mon Oct 05 16:00:00 CST 2009, time=2009-10-05, status=1, ipAttribution=)]
Submission date: 22 Mar 2012 Major Revision: 7 May 2012 Revision received: 12 Jul 2012 Minor Revision: 14 Aug 2012 Revision received: 20 Aug 2012 Accepted: 24 Aug 2012
[GetPortalCommentsPageByObjectIdResponse(id=509070, encodeId=95d45090e0b0, content=一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=383, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723f1608660, createdName=fengjie741, createdTime=Sat Jan 10 11:45:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502951, encodeId=5a94502951ef, content=经典期刊~等待雄起啊~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri May 16 16:00:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502162, encodeId=5a5650216217, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：2010年11月底抱着试试看的心情，刚写完的manuscript第一次就投给了BLOOD，没想到格外幸运，两个审稿人一审就给出了 minor revision 的意见（2011年1月，审稿用时8周），比较少见，大体上非常supportive，于是花了两个月补充了两三个小实验，修改了一些文章细节，追加了一些讨论分析；2011年4月投回去，然后过了一周就接收了。后来这几年里自己的其他文章又陆续投过比BLOOD低分的杂志，都没再有如此顺利的呵呵，都是先major revision再minor revision的折腾，相信同行们都理解这些历程的~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=路人熊医师, createdTime=Fri Apr 04 08:52:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490209, encodeId=81654902094b, content=审稿速度:2.0<br>经验分享：今年文章 第一次投BLOOD， 只是试一试而已， 侥幸通过。 两位评审还比较NICE， 没有提出多少补充实验。。。文章要求数据很牢靠， 总结了前十几年在自己研究领域课题的争议， 提出自己的观点给予验证，实验结果不仅需要现象， 还要机制说明。 给大家参考一下自己投稿的时间！ <br> <br> Submission date: 22 Mar 2012 <br> Major Revision: 7 May 2012 <br> Revision received: 12 Jul 2012 <br> Minor Revision: 14 Aug 2012 <br> Revision received: 20 Aug 2012 <br> Accepted: 24 Aug 2012 <br> <br> 谢谢对大家的支持和努力！再接再厉做好科研！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea66634, createdName=alansb, createdTime=Sun Aug 26 08:00:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=475571, encodeId=04ea4e557167, content=出版周期：Semimonthly <br> 出版ISSN：0006-4971 <br> Blood是隶属于美国血液学会ASH的周刊，是血液领域的顶级杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e7c34764, createdName=marshlin, createdTime=Wed Jun 29 12:10:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=470004, encodeId=d4744e00041e, content=杂志名称： BLOOD <br> 专业领域： 血液，移植，免疫，干细胞，肿瘤 <br> 杂志国家： 美国 <br> 投稿日期：16 Jul 2009 <br> 投稿方式（投稿系统或者邮寄，如果有投稿系统请附上投稿链接）： <br> 在线投稿 http://submit.bloodjournal.org/ <br> 修回日期： 无 <br> 修改方式（大修，小修，拒稿）：拒稿 <br> 接受日期： 无 <br> 是否收版面费： 还不知道呢，呵呵。 <br> 分享的经验或教训：感觉对我们搞基础研究的，BLOOD这种杂志越来越难投了，杂志上很多文章都是很偏临床的，基础的很少。该杂志效率还是很高的，如果送外审的话，也是一个月给决定。我们这次因为两个reviewer意见不太一致，所以又找了第三个reviewer，（所以花了5个星期做决定）结果后者给了大修的建议，综合起来意见比较负面，编辑决定拒稿。 <br> <br> 附上decison letter <br> Dear Dr. XXX: <br> <br> Expert reviewers in the field have evaluated your manuscript, referenced above. Unfortunately, our final decision is that your paper is not acceptable for publication in Blood. You can log into Blood Bench>Press at http://submit.bloodjournal.org and go to the queue "Manuscripts with Decisions" to <br> find this submission and access any reviewer comments. <br> <br> Concerns were raised about the reliance on a small number of cell lines and the reasons for selecting XXXX over numerous other possible candidates. <br> <br> You will appreciate that the number of manuscripts submitted to Blood for publication consideration is very high and that we are currently able to accept no more than 20% of submitted manuscripts. <br> <br> Consequently, the journal can only accept papers that receive a high priority rating based on the definitive and novel nature of the findings reported. <br> <br> I regret the negative decision on this manuscript, but thank you for sending it to Blood for consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=river33617, createdTime=Fri Jan 01 17:20:00 CST 2010, time=2010-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469745, encodeId=41a2469e459c, content=我们实验室几乎每年都有，虽然说是血液病中顶级杂志，但在国内，仍然与CNS级差得远。一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=496, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CAS, createdTime=Tue Dec 15 14:22:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469450, encodeId=0cac469450b7, content=一审周期在1个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ZHAO, createdTime=Fri Nov 20 15:56:00 CST 2009, time=2009-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469363, encodeId=3dce46936369, content=血液领域的最权威杂志了，国内有几个投稿大户，如陈国强，陈竺那里，发表起来不太难。但是要求实验非常完善，技术方法都要求新，而且有原创的发现。 <br> 当然，如果这个发不了，可以考虑低一层次的《白血病》，也不错。另外，现在不少牛人，好文章也逐步离开blood，跑其它的地方去了哦，如nature medicine等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=394, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=血液科医生, createdTime=Mon Oct 05 16:00:00 CST 2009, time=2009-10-05, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=509070, encodeId=95d45090e0b0, content=一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=383, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723f1608660, createdName=fengjie741, createdTime=Sat Jan 10 11:45:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502951, encodeId=5a94502951ef, content=经典期刊~等待雄起啊~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri May 16 16:00:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502162, encodeId=5a5650216217, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：2010年11月底抱着试试看的心情，刚写完的manuscript第一次就投给了BLOOD，没想到格外幸运，两个审稿人一审就给出了 minor revision 的意见（2011年1月，审稿用时8周），比较少见，大体上非常supportive，于是花了两个月补充了两三个小实验，修改了一些文章细节，追加了一些讨论分析；2011年4月投回去，然后过了一周就接收了。后来这几年里自己的其他文章又陆续投过比BLOOD低分的杂志，都没再有如此顺利的呵呵，都是先major revision再minor revision的折腾，相信同行们都理解这些历程的~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=路人熊医师, createdTime=Fri Apr 04 08:52:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490209, encodeId=81654902094b, content=审稿速度:2.0<br>经验分享：今年文章 第一次投BLOOD， 只是试一试而已， 侥幸通过。 两位评审还比较NICE， 没有提出多少补充实验。。。文章要求数据很牢靠， 总结了前十几年在自己研究领域课题的争议， 提出自己的观点给予验证，实验结果不仅需要现象， 还要机制说明。 给大家参考一下自己投稿的时间！ <br> <br> Submission date: 22 Mar 2012 <br> Major Revision: 7 May 2012 <br> Revision received: 12 Jul 2012 <br> Minor Revision: 14 Aug 2012 <br> Revision received: 20 Aug 2012 <br> Accepted: 24 Aug 2012 <br> <br> 谢谢对大家的支持和努力！再接再厉做好科研！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea66634, createdName=alansb, createdTime=Sun Aug 26 08:00:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=475571, encodeId=04ea4e557167, content=出版周期：Semimonthly <br> 出版ISSN：0006-4971 <br> Blood是隶属于美国血液学会ASH的周刊，是血液领域的顶级杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e7c34764, createdName=marshlin, createdTime=Wed Jun 29 12:10:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=470004, encodeId=d4744e00041e, content=杂志名称： BLOOD <br> 专业领域： 血液，移植，免疫，干细胞，肿瘤 <br> 杂志国家： 美国 <br> 投稿日期：16 Jul 2009 <br> 投稿方式（投稿系统或者邮寄，如果有投稿系统请附上投稿链接）： <br> 在线投稿 http://submit.bloodjournal.org/ <br> 修回日期： 无 <br> 修改方式（大修，小修，拒稿）：拒稿 <br> 接受日期： 无 <br> 是否收版面费： 还不知道呢，呵呵。 <br> 分享的经验或教训：感觉对我们搞基础研究的，BLOOD这种杂志越来越难投了，杂志上很多文章都是很偏临床的，基础的很少。该杂志效率还是很高的，如果送外审的话，也是一个月给决定。我们这次因为两个reviewer意见不太一致，所以又找了第三个reviewer，（所以花了5个星期做决定）结果后者给了大修的建议，综合起来意见比较负面，编辑决定拒稿。 <br> <br> 附上decison letter <br> Dear Dr. XXX: <br> <br> Expert reviewers in the field have evaluated your manuscript, referenced above. Unfortunately, our final decision is that your paper is not acceptable for publication in Blood. You can log into Blood Bench>Press at http://submit.bloodjournal.org and go to the queue "Manuscripts with Decisions" to <br> find this submission and access any reviewer comments. <br> <br> Concerns were raised about the reliance on a small number of cell lines and the reasons for selecting XXXX over numerous other possible candidates. <br> <br> You will appreciate that the number of manuscripts submitted to Blood for publication consideration is very high and that we are currently able to accept no more than 20% of submitted manuscripts. <br> <br> Consequently, the journal can only accept papers that receive a high priority rating based on the definitive and novel nature of the findings reported. <br> <br> I regret the negative decision on this manuscript, but thank you for sending it to Blood for consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=river33617, createdTime=Fri Jan 01 17:20:00 CST 2010, time=2010-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469745, encodeId=41a2469e459c, content=我们实验室几乎每年都有，虽然说是血液病中顶级杂志，但在国内，仍然与CNS级差得远。一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=496, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CAS, createdTime=Tue Dec 15 14:22:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469450, encodeId=0cac469450b7, content=一审周期在1个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ZHAO, createdTime=Fri Nov 20 15:56:00 CST 2009, time=2009-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469363, encodeId=3dce46936369, content=血液领域的最权威杂志了，国内有几个投稿大户，如陈国强，陈竺那里，发表起来不太难。但是要求实验非常完善，技术方法都要求新，而且有原创的发现。 <br> 当然，如果这个发不了，可以考虑低一层次的《白血病》，也不错。另外，现在不少牛人，好文章也逐步离开blood，跑其它的地方去了哦，如nature medicine等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=394, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=血液科医生, createdTime=Mon Oct 05 16:00:00 CST 2009, time=2009-10-05, status=1, ipAttribution=)]
Expert reviewers in the field have evaluated your manuscript, referenced above. Unfortunately, our final decision is that your paper is not acceptable for publication in Blood. You can log into Blood Bench>Press at http://submit.bloodjournal.org and go to the queue "Manuscripts with Decisions" to find this submission and access any reviewer comments.
Concerns were raised about the reliance on a small number of cell lines and the reasons for selecting XXXX over numerous other possible candidates.
You will appreciate that the number of manuscripts submitted to Blood for publication consideration is very high and that we are currently able to accept no more than 20% of submitted manuscripts.
Consequently, the journal can only accept papers that receive a high priority rating based on the definitive and novel nature of the findings reported.
I regret the negative decision on this manuscript, but thank you for sending it to Blood for consideration.
[GetPortalCommentsPageByObjectIdResponse(id=509070, encodeId=95d45090e0b0, content=一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=383, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723f1608660, createdName=fengjie741, createdTime=Sat Jan 10 11:45:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502951, encodeId=5a94502951ef, content=经典期刊~等待雄起啊~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri May 16 16:00:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502162, encodeId=5a5650216217, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：2010年11月底抱着试试看的心情，刚写完的manuscript第一次就投给了BLOOD，没想到格外幸运，两个审稿人一审就给出了 minor revision 的意见（2011年1月，审稿用时8周），比较少见，大体上非常supportive，于是花了两个月补充了两三个小实验，修改了一些文章细节，追加了一些讨论分析；2011年4月投回去，然后过了一周就接收了。后来这几年里自己的其他文章又陆续投过比BLOOD低分的杂志，都没再有如此顺利的呵呵，都是先major revision再minor revision的折腾，相信同行们都理解这些历程的~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=路人熊医师, createdTime=Fri Apr 04 08:52:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490209, encodeId=81654902094b, content=审稿速度:2.0<br>经验分享：今年文章 第一次投BLOOD， 只是试一试而已， 侥幸通过。 两位评审还比较NICE， 没有提出多少补充实验。。。文章要求数据很牢靠， 总结了前十几年在自己研究领域课题的争议， 提出自己的观点给予验证，实验结果不仅需要现象， 还要机制说明。 给大家参考一下自己投稿的时间！ <br> <br> Submission date: 22 Mar 2012 <br> Major Revision: 7 May 2012 <br> Revision received: 12 Jul 2012 <br> Minor Revision: 14 Aug 2012 <br> Revision received: 20 Aug 2012 <br> Accepted: 24 Aug 2012 <br> <br> 谢谢对大家的支持和努力！再接再厉做好科研！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea66634, createdName=alansb, createdTime=Sun Aug 26 08:00:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=475571, encodeId=04ea4e557167, content=出版周期：Semimonthly <br> 出版ISSN：0006-4971 <br> Blood是隶属于美国血液学会ASH的周刊，是血液领域的顶级杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e7c34764, createdName=marshlin, createdTime=Wed Jun 29 12:10:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=470004, encodeId=d4744e00041e, content=杂志名称： BLOOD <br> 专业领域： 血液，移植，免疫，干细胞，肿瘤 <br> 杂志国家： 美国 <br> 投稿日期：16 Jul 2009 <br> 投稿方式（投稿系统或者邮寄，如果有投稿系统请附上投稿链接）： <br> 在线投稿 http://submit.bloodjournal.org/ <br> 修回日期： 无 <br> 修改方式（大修，小修，拒稿）：拒稿 <br> 接受日期： 无 <br> 是否收版面费： 还不知道呢，呵呵。 <br> 分享的经验或教训：感觉对我们搞基础研究的，BLOOD这种杂志越来越难投了，杂志上很多文章都是很偏临床的，基础的很少。该杂志效率还是很高的，如果送外审的话，也是一个月给决定。我们这次因为两个reviewer意见不太一致，所以又找了第三个reviewer，（所以花了5个星期做决定）结果后者给了大修的建议，综合起来意见比较负面，编辑决定拒稿。 <br> <br> 附上decison letter <br> Dear Dr. XXX: <br> <br> Expert reviewers in the field have evaluated your manuscript, referenced above. Unfortunately, our final decision is that your paper is not acceptable for publication in Blood. You can log into Blood Bench>Press at http://submit.bloodjournal.org and go to the queue "Manuscripts with Decisions" to <br> find this submission and access any reviewer comments. <br> <br> Concerns were raised about the reliance on a small number of cell lines and the reasons for selecting XXXX over numerous other possible candidates. <br> <br> You will appreciate that the number of manuscripts submitted to Blood for publication consideration is very high and that we are currently able to accept no more than 20% of submitted manuscripts. <br> <br> Consequently, the journal can only accept papers that receive a high priority rating based on the definitive and novel nature of the findings reported. <br> <br> I regret the negative decision on this manuscript, but thank you for sending it to Blood for consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=river33617, createdTime=Fri Jan 01 17:20:00 CST 2010, time=2010-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469745, encodeId=41a2469e459c, content=我们实验室几乎每年都有，虽然说是血液病中顶级杂志，但在国内，仍然与CNS级差得远。一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=496, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CAS, createdTime=Tue Dec 15 14:22:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469450, encodeId=0cac469450b7, content=一审周期在1个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ZHAO, createdTime=Fri Nov 20 15:56:00 CST 2009, time=2009-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469363, encodeId=3dce46936369, content=血液领域的最权威杂志了，国内有几个投稿大户，如陈国强，陈竺那里，发表起来不太难。但是要求实验非常完善，技术方法都要求新，而且有原创的发现。 <br> 当然，如果这个发不了，可以考虑低一层次的《白血病》，也不错。另外，现在不少牛人，好文章也逐步离开blood，跑其它的地方去了哦，如nature medicine等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=394, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=血液科医生, createdTime=Mon Oct 05 16:00:00 CST 2009, time=2009-10-05, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=509070, encodeId=95d45090e0b0, content=一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=383, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723f1608660, createdName=fengjie741, createdTime=Sat Jan 10 11:45:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502951, encodeId=5a94502951ef, content=经典期刊~等待雄起啊~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri May 16 16:00:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502162, encodeId=5a5650216217, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：2010年11月底抱着试试看的心情，刚写完的manuscript第一次就投给了BLOOD，没想到格外幸运，两个审稿人一审就给出了 minor revision 的意见（2011年1月，审稿用时8周），比较少见，大体上非常supportive，于是花了两个月补充了两三个小实验，修改了一些文章细节，追加了一些讨论分析；2011年4月投回去，然后过了一周就接收了。后来这几年里自己的其他文章又陆续投过比BLOOD低分的杂志，都没再有如此顺利的呵呵，都是先major revision再minor revision的折腾，相信同行们都理解这些历程的~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=路人熊医师, createdTime=Fri Apr 04 08:52:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490209, encodeId=81654902094b, content=审稿速度:2.0<br>经验分享：今年文章 第一次投BLOOD， 只是试一试而已， 侥幸通过。 两位评审还比较NICE， 没有提出多少补充实验。。。文章要求数据很牢靠， 总结了前十几年在自己研究领域课题的争议， 提出自己的观点给予验证，实验结果不仅需要现象， 还要机制说明。 给大家参考一下自己投稿的时间！ <br> <br> Submission date: 22 Mar 2012 <br> Major Revision: 7 May 2012 <br> Revision received: 12 Jul 2012 <br> Minor Revision: 14 Aug 2012 <br> Revision received: 20 Aug 2012 <br> Accepted: 24 Aug 2012 <br> <br> 谢谢对大家的支持和努力！再接再厉做好科研！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea66634, createdName=alansb, createdTime=Sun Aug 26 08:00:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=475571, encodeId=04ea4e557167, content=出版周期：Semimonthly <br> 出版ISSN：0006-4971 <br> Blood是隶属于美国血液学会ASH的周刊，是血液领域的顶级杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e7c34764, createdName=marshlin, createdTime=Wed Jun 29 12:10:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=470004, encodeId=d4744e00041e, content=杂志名称： BLOOD <br> 专业领域： 血液，移植，免疫，干细胞，肿瘤 <br> 杂志国家： 美国 <br> 投稿日期：16 Jul 2009 <br> 投稿方式（投稿系统或者邮寄，如果有投稿系统请附上投稿链接）： <br> 在线投稿 http://submit.bloodjournal.org/ <br> 修回日期： 无 <br> 修改方式（大修，小修，拒稿）：拒稿 <br> 接受日期： 无 <br> 是否收版面费： 还不知道呢，呵呵。 <br> 分享的经验或教训：感觉对我们搞基础研究的，BLOOD这种杂志越来越难投了，杂志上很多文章都是很偏临床的，基础的很少。该杂志效率还是很高的，如果送外审的话，也是一个月给决定。我们这次因为两个reviewer意见不太一致，所以又找了第三个reviewer，（所以花了5个星期做决定）结果后者给了大修的建议，综合起来意见比较负面，编辑决定拒稿。 <br> <br> 附上decison letter <br> Dear Dr. XXX: <br> <br> Expert reviewers in the field have evaluated your manuscript, referenced above. Unfortunately, our final decision is that your paper is not acceptable for publication in Blood. You can log into Blood Bench>Press at http://submit.bloodjournal.org and go to the queue "Manuscripts with Decisions" to <br> find this submission and access any reviewer comments. <br> <br> Concerns were raised about the reliance on a small number of cell lines and the reasons for selecting XXXX over numerous other possible candidates. <br> <br> You will appreciate that the number of manuscripts submitted to Blood for publication consideration is very high and that we are currently able to accept no more than 20% of submitted manuscripts. <br> <br> Consequently, the journal can only accept papers that receive a high priority rating based on the definitive and novel nature of the findings reported. <br> <br> I regret the negative decision on this manuscript, but thank you for sending it to Blood for consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=river33617, createdTime=Fri Jan 01 17:20:00 CST 2010, time=2010-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469745, encodeId=41a2469e459c, content=我们实验室几乎每年都有，虽然说是血液病中顶级杂志，但在国内，仍然与CNS级差得远。一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=496, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CAS, createdTime=Tue Dec 15 14:22:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469450, encodeId=0cac469450b7, content=一审周期在1个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ZHAO, createdTime=Fri Nov 20 15:56:00 CST 2009, time=2009-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469363, encodeId=3dce46936369, content=血液领域的最权威杂志了，国内有几个投稿大户，如陈国强，陈竺那里，发表起来不太难。但是要求实验非常完善，技术方法都要求新，而且有原创的发现。 <br> 当然，如果这个发不了，可以考虑低一层次的《白血病》，也不错。另外，现在不少牛人，好文章也逐步离开blood，跑其它的地方去了哦，如nature medicine等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=394, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=血液科医生, createdTime=Mon Oct 05 16:00:00 CST 2009, time=2009-10-05, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=509070, encodeId=95d45090e0b0, content=一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=383, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723f1608660, createdName=fengjie741, createdTime=Sat Jan 10 11:45:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502951, encodeId=5a94502951ef, content=经典期刊~等待雄起啊~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri May 16 16:00:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502162, encodeId=5a5650216217, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：2010年11月底抱着试试看的心情，刚写完的manuscript第一次就投给了BLOOD，没想到格外幸运，两个审稿人一审就给出了 minor revision 的意见（2011年1月，审稿用时8周），比较少见，大体上非常supportive，于是花了两个月补充了两三个小实验，修改了一些文章细节，追加了一些讨论分析；2011年4月投回去，然后过了一周就接收了。后来这几年里自己的其他文章又陆续投过比BLOOD低分的杂志，都没再有如此顺利的呵呵，都是先major revision再minor revision的折腾，相信同行们都理解这些历程的~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=路人熊医师, createdTime=Fri Apr 04 08:52:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490209, encodeId=81654902094b, content=审稿速度:2.0<br>经验分享：今年文章 第一次投BLOOD， 只是试一试而已， 侥幸通过。 两位评审还比较NICE， 没有提出多少补充实验。。。文章要求数据很牢靠， 总结了前十几年在自己研究领域课题的争议， 提出自己的观点给予验证，实验结果不仅需要现象， 还要机制说明。 给大家参考一下自己投稿的时间！ <br> <br> Submission date: 22 Mar 2012 <br> Major Revision: 7 May 2012 <br> Revision received: 12 Jul 2012 <br> Minor Revision: 14 Aug 2012 <br> Revision received: 20 Aug 2012 <br> Accepted: 24 Aug 2012 <br> <br> 谢谢对大家的支持和努力！再接再厉做好科研！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea66634, createdName=alansb, createdTime=Sun Aug 26 08:00:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=475571, encodeId=04ea4e557167, content=出版周期：Semimonthly <br> 出版ISSN：0006-4971 <br> Blood是隶属于美国血液学会ASH的周刊，是血液领域的顶级杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e7c34764, createdName=marshlin, createdTime=Wed Jun 29 12:10:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=470004, encodeId=d4744e00041e, content=杂志名称： BLOOD <br> 专业领域： 血液，移植，免疫，干细胞，肿瘤 <br> 杂志国家： 美国 <br> 投稿日期：16 Jul 2009 <br> 投稿方式（投稿系统或者邮寄，如果有投稿系统请附上投稿链接）： <br> 在线投稿 http://submit.bloodjournal.org/ <br> 修回日期： 无 <br> 修改方式（大修，小修，拒稿）：拒稿 <br> 接受日期： 无 <br> 是否收版面费： 还不知道呢，呵呵。 <br> 分享的经验或教训：感觉对我们搞基础研究的，BLOOD这种杂志越来越难投了，杂志上很多文章都是很偏临床的，基础的很少。该杂志效率还是很高的，如果送外审的话，也是一个月给决定。我们这次因为两个reviewer意见不太一致，所以又找了第三个reviewer，（所以花了5个星期做决定）结果后者给了大修的建议，综合起来意见比较负面，编辑决定拒稿。 <br> <br> 附上decison letter <br> Dear Dr. XXX: <br> <br> Expert reviewers in the field have evaluated your manuscript, referenced above. Unfortunately, our final decision is that your paper is not acceptable for publication in Blood. You can log into Blood Bench>Press at http://submit.bloodjournal.org and go to the queue "Manuscripts with Decisions" to <br> find this submission and access any reviewer comments. <br> <br> Concerns were raised about the reliance on a small number of cell lines and the reasons for selecting XXXX over numerous other possible candidates. <br> <br> You will appreciate that the number of manuscripts submitted to Blood for publication consideration is very high and that we are currently able to accept no more than 20% of submitted manuscripts. <br> <br> Consequently, the journal can only accept papers that receive a high priority rating based on the definitive and novel nature of the findings reported. <br> <br> I regret the negative decision on this manuscript, but thank you for sending it to Blood for consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=river33617, createdTime=Fri Jan 01 17:20:00 CST 2010, time=2010-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469745, encodeId=41a2469e459c, content=我们实验室几乎每年都有，虽然说是血液病中顶级杂志，但在国内，仍然与CNS级差得远。一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=496, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CAS, createdTime=Tue Dec 15 14:22:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469450, encodeId=0cac469450b7, content=一审周期在1个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ZHAO, createdTime=Fri Nov 20 15:56:00 CST 2009, time=2009-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469363, encodeId=3dce46936369, content=血液领域的最权威杂志了，国内有几个投稿大户，如陈国强，陈竺那里，发表起来不太难。但是要求实验非常完善，技术方法都要求新，而且有原创的发现。 <br> 当然，如果这个发不了，可以考虑低一层次的《白血病》，也不错。另外，现在不少牛人，好文章也逐步离开blood，跑其它的地方去了哦，如nature medicine等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=394, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=血液科医生, createdTime=Mon Oct 05 16:00:00 CST 2009, time=2009-10-05, status=1, ipAttribution=)]
一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难
383
经典期刊~等待雄起啊~
390
审稿速度:2.0 | 投稿命中率:25.0
经验分享：2010年11月底抱着试试看的心情，刚写完的manuscript第一次就投给了BLOOD，没想到格外幸运，两个审稿人一审就给出了 minor revision 的意见（2011年1月，审稿用时8周），比较少见，大体上非常supportive，于是花了两个月补充了两三个小实验，修改了一些文章细节，追加了一些讨论分析；2011年4月投回去，然后过了一周就接收了。后来这几年里自己的其他文章又陆续投过比BLOOD低分的杂志，都没再有如此顺利的呵呵，都是先major revision再minor revision的折腾，相信同行们都理解这些历程的~
415
审稿速度:2.0
经验分享：今年文章 第一次投BLOOD， 只是试一试而已， 侥幸通过。 两位评审还比较NICE， 没有提出多少补充实验。。。文章要求数据很牢靠， 总结了前十几年在自己研究领域课题的争议， 提出自己的观点给予验证，实验结果不仅需要现象， 还要机制说明。 给大家参考一下自己投稿的时间！
Submission date: 22 Mar 2012
Major Revision: 7 May 2012
Revision received: 12 Jul 2012
Minor Revision: 14 Aug 2012
Revision received: 20 Aug 2012
Accepted: 24 Aug 2012
谢谢对大家的支持和努力！再接再厉做好科研！
468
出版周期：Semimonthly
出版ISSN：0006-4971
Blood是隶属于美国血液学会ASH的周刊，是血液领域的顶级杂志。
417
杂志名称： BLOOD
专业领域： 血液，移植，免疫，干细胞，肿瘤
杂志国家： 美国
投稿日期：16 Jul 2009
投稿方式（投稿系统或者邮寄，如果有投稿系统请附上投稿链接）：
在线投稿 http://submit.bloodjournal.org/
修回日期： 无
修改方式（大修，小修，拒稿）：拒稿
接受日期： 无
是否收版面费： 还不知道呢，呵呵。
分享的经验或教训：感觉对我们搞基础研究的，BLOOD这种杂志越来越难投了，杂志上很多文章都是很偏临床的，基础的很少。该杂志效率还是很高的，如果送外审的话，也是一个月给决定。我们这次因为两个reviewer意见不太一致，所以又找了第三个reviewer，（所以花了5个星期做决定）结果后者给了大修的建议，综合起来意见比较负面，编辑决定拒稿。
附上decison letter
Dear Dr. XXX:
Expert reviewers in the field have evaluated your manuscript, referenced above. Unfortunately, our final decision is that your paper is not acceptable for publication in Blood. You can log into Blood Bench>Press at http://submit.bloodjournal.org and go to the queue "Manuscripts with Decisions" to
find this submission and access any reviewer comments.
Concerns were raised about the reliance on a small number of cell lines and the reasons for selecting XXXX over numerous other possible candidates.
You will appreciate that the number of manuscripts submitted to Blood for publication consideration is very high and that we are currently able to accept no more than 20% of submitted manuscripts.
Consequently, the journal can only accept papers that receive a high priority rating based on the definitive and novel nature of the findings reported.
I regret the negative decision on this manuscript, but thank you for sending it to Blood for consideration.
441
我们实验室几乎每年都有，虽然说是血液病中顶级杂志，但在国内，仍然与CNS级差得远。一般来说，需要创新，这是肯定的，然后就是方法学十分完善，不要有漏洞和疑问。发表也不是太难
496
一审周期在1个月左右。
464
血液领域的最权威杂志了，国内有几个投稿大户，如陈国强，陈竺那里，发表起来不太难。但是要求实验非常完善，技术方法都要求新，而且有原创的发现。
当然，如果这个发不了，可以考虑低一层次的《白血病》，也不错。另外，现在不少牛人，好文章也逐步离开blood，跑其它的地方去了哦，如nature medicine等
394